Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.

De S, Lindner DJ, Coleman CJ, Wildey G, Dowlati A, Stark GR.

Cancer Res. 2018 May 1;78(9):2396-2406. doi: 10.1158/0008-5472.CAN-17-1920. Epub 2018 Feb 13.

PMID:
29440145
2.

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer.

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A.

Oncotarget. 2017 Aug 28;8(43):73745-73756. doi: 10.18632/oncotarget.20572. eCollection 2017 Sep 26.

3.

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).

Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D.

J Thorac Oncol. 2017 Apr;12(4):704-713. doi: 10.1016/j.jtho.2016.12.011. Epub 2016 Dec 19.

4.

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.

Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, Dowlati A.

Oncotarget. 2017 Jan 24;8(4):5992-6002. doi: 10.18632/oncotarget.13362.

5.

Genomic alterations in small cell lung cancer and their clinical relevance.

Wildey G, Dowlati A.

Transl Lung Cancer Res. 2016 Aug;5(4):450-1. doi: 10.21037/tlcr.2016.07.05. No abstract available.

6.

Clinical correlation of extensive-stage small-cell lung cancer genomics.

Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, Miron A, Yang M, Sharma N, Fu P, Wildey G.

Ann Oncol. 2016 Apr;27(4):642-7. doi: 10.1093/annonc/mdw005. Epub 2016 Jan 22.

7.

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.

Greenberg EF, McColl KS, Zhong F, Wildey G, Dowlati A, Distelhorst CW.

Cell Death Dis. 2015 Dec 31;6:e2034. doi: 10.1038/cddis.2015.355.

8.

CD30 is a potential therapeutic target in malignant mesothelioma.

Dabir S, Kresak A, Yang M, Fu P, Wildey G, Dowlati A.

Mol Cancer Ther. 2015 Mar;14(3):740-6. doi: 10.1158/1535-7163.MCT-14-0972. Epub 2015 Jan 14.

9.

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.

Abbas R, McColl KS, Kresak A, Yang M, Chen Y, Fu P, Wildey G, Dowlati A.

Cancer Med. 2015 Mar;4(3):325-32. doi: 10.1002/cam4.372. Epub 2015 Jan 9.

10.

Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer.

Wildey G, Chen Y, Lent I, Stetson L, Pink J, Barnholtz-Sloan JS, Dowlati A.

PLoS One. 2014 Sep 8;9(9):e106784. doi: 10.1371/journal.pone.0106784. eCollection 2014.

11.

Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.

Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, Wildey G, Dowlati A.

Clin Cancer Res. 2014 Oct 1;20(19):5124-32. doi: 10.1158/1078-0432.CCR-14-1233. Epub 2014 Aug 14.

12.

RET mutation and expression in small-cell lung cancer.

Dabir S, Babakoohi S, Kluge A, Morrow JJ, Kresak A, Yang M, MacPherson D, Wildey G, Dowlati A.

J Thorac Oncol. 2014 Sep;9(9):1316-23. doi: 10.1097/JTO.0000000000000234.

13.

Defining subgroups of small-cell lung cancer.

Dowlati A, Wildey G.

J Thorac Oncol. 2014 Jun;9(6):750-1. doi: 10.1097/JTO.0000000000000176. No abstract available.

14.

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Dabir S, Kluge A, McColl K, Liu Y, Lam M, Halmos B, Wildey G, Dowlati A.

Int J Cancer. 2014 Mar 1;134(5):1045-54. doi: 10.1002/ijc.28448. Epub 2013 Sep 23.

15.

Supplements in human islet culture: human serum albumin is inferior to fetal bovine serum.

Avgoustiniatos ES, Scott WE 3rd, Suszynski TM, Schuurman HJ, Nelson RA, Rozak PR, Mueller KR, Balamurugan AN, Ansite JD, Fraga DW, Friberg AS, Wildey GM, Tanaka T, Lyons CA, Sutherland DE, Hering BJ, Papas KK.

Cell Transplant. 2012;21(12):2805-14. doi: 10.3727/096368912X653138. Epub 2012 Aug 2.

PMID:
22863057
16.

Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells.

Wildey GM, Howe PH.

J Biol Chem. 2009 Jul 24;284(30):20227-39. doi: 10.1074/jbc.M109.027201. Epub 2009 Jun 3.

17.

Transforming growth factor beta (TGFbeta)-induced apoptosis: the rise & fall of Bim.

Ramesh S, Wildey GM, Howe PH.

Cell Cycle. 2009 Jan 1;8(1):11-7. Epub 2009 Jan 30. Review.

18.

Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner.

Jiang G, Yang HR, Wang L, Wildey GM, Fung J, Qian S, Lu L.

Transplantation. 2008 Dec 15;86(11):1492-502. doi: 10.1097/TP.0b013e31818bfd13.

19.

TGF beta-mediated BIM expression and apoptosis are regulated through SMAD3-dependent expression of the MAPK phosphatase MKP2.

Ramesh S, Qi XJ, Wildey GM, Robinson J, Molkentin J, Letterio J, Howe PH.

EMBO Rep. 2008 Oct;9(10):990-7. doi: 10.1038/embor.2008.158. Epub 2008 Aug 15.

20.

The ATP/DNA ratio is a better indicator of islet cell viability than the ADP/ATP ratio.

Suszynski TM, Wildey GM, Falde EJ, Cline GW, Maynard KS, Ko N, Sotiris J, Naji A, Hering BJ, Papas KK.

Transplant Proc. 2008 Mar;40(2):346-50. doi: 10.1016/j.transproceed.2008.01.061.

21.

Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice.

Papas KK, Colton CK, Nelson RA, Rozak PR, Avgoustiniatos ES, Scott WE 3rd, Wildey GM, Pisania A, Weir GC, Hering BJ.

Am J Transplant. 2007 Mar;7(3):707-13. Epub 2007 Jan 4.

22.

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function.

Qi XJ, Wildey GM, Howe PH.

J Biol Chem. 2006 Jan 13;281(2):813-23. Epub 2005 Nov 10.

23.

Transforming growth factor-beta1 in a sterilized tissue derived from the pig small intestine submucosa.

McDevitt CA, Wildey GM, Cutrone RM.

J Biomed Mater Res A. 2003 Nov 1;67(2):637-40.

PMID:
14566807
24.
25.
26.

Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta -induced growth inhibition and apoptosis.

Patil S, Wildey GM, Brown TL, Choy L, Derynck R, Howe PH.

J Biol Chem. 2000 Dec 8;275(49):38363-70.

27.

Matrix protein mRNA levels in canine meniscus cells in vitro.

Wildey GM, McDevitt CA.

Arch Biochem Biophys. 1998 May 1;353(1):10-5.

PMID:
9578595
28.

Cloning and tissue expression of the rat RAB 3C GTP-binding protein.

Viggeswarapu M, Wildey GM.

Biochem Biophys Res Commun. 1996 Oct 23;227(3):645-50.

PMID:
8885988
29.
30.

Isolation of cDNA clones and tissue expression of rat ral A and ral B GTP-binding proteins.

Wildey GM, Viggeswarapu M, Rim S, Denker JK.

Biochem Biophys Res Commun. 1993 Jul 15;194(1):552-9.

PMID:
7687439
31.

Detection of low molecular weight GTP-binding proteins associated with rat atrial secretory granules.

Wildey GM, Matyas AE.

J Mol Cell Cardiol. 1993 Apr;25(4):459-68.

PMID:
8340935
32.

Phosphorylation state of pro-atrial natriuretic factor in rat atrial secretory granules.

Wildey GM, Fischman AJ, Margolies MN, Graham RM, Homcy CJ.

Endocrinology. 1990 Dec;127(6):2839-48.

PMID:
2174336
33.

Stimulation of the phosphorylation of uridine in skeletal muscle by insulin and vanadate.

Haugaard N, Torbati A, Smithgall T, Wildey G.

Mol Cell Biochem. 1990 Mar 5;93(1):13-9.

PMID:
2158618
34.
35.

Specificity of serine proteases for cleavage sites on proatrial natriuretic factor.

Fischman AJ, Wildey GM, Matsueda GR, Margolies MN, Zisfein JB, Homcy CJ, Graham RM.

Peptides. 1988 Nov-Dec;9(6):1275-83.

PMID:
2977643
36.

Cellular processing of pro-atrial natriuretic factor (pro-ANF): studies using an antiserum that selectively binds ANF-(99-126) after its cleavage from pro-ANF.

Wildey GM, Fischman AJ, Fallon JT, Matsueda GR, Zisfein JB, Preibisch G, Seipke G, Homcy CJ, Graham RM.

Endocrinology. 1988 Oct;123(4):2054-61.

PMID:
2970960
37.

Characterization and purification of a protease in serum that cleaves proatrial natriuretic factor (ProANF) to its circulating forms.

Zisfein JB, Graham RM, Dreskin SV, Wildey GM, Fischman AJ, Homcy CJ.

Biochemistry. 1987 Dec 29;26(26):8690-7.

PMID:
2964868
38.
39.
40.

Molecular forms of immunoactive atrial natriuretic peptide in the rat hypothalamus and atrium.

Glembotski CC, Wildey GM, Gibson TR.

Biochem Biophys Res Commun. 1985 Jun 28;129(3):671-8.

PMID:
3160349
41.

Metabolic effects of acarbose administration in normal and diabetic rats.

Haugaard N, Hess ME, Locke CL, Torbati A, Wildey G.

Biochem Pharmacol. 1984 May 1;33(9):1503-8.

PMID:
6732866
42.

Phosphatidylinositol turnover and cellular function.

Gil DW, Brown SA, Seeholzer SH, Wildey GM.

Life Sci. 1983 May 2;32(18):2043-6. No abstract available.

PMID:
6843281
43.

The relationship between uracil nucleotide concentrations and glycogen synthesis in hepatocytes from fed and fasted rats.

Songu E, Haugaard ES, Wildey G, Haugaard N.

Metabolism. 1981 Feb;30(2):119-22.

PMID:
7464560

Supplemental Content

Loading ...
Support Center